Titelbild

Supervisory Board

 
Portrait

Paul Sekhri (Chairman)

Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Lt. Prior to joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009 Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.

Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.

 
Portrait

Paul Sekhri (Chairman)

Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Lt. Prior to joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009 Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.

Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.

 
Portrait

Peter Finan Ph.D., Epidarex Capital (Vice Chairman)

Dr. Peter Finan has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining Epidarex, Dr. Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Dr. Finan worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as the Head of Biology at Karus Therapeutics. Dr. Finan currently serves on the Board of Directors of Caldan Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd., Mironid Ltd., and Topas Therapeutics Ltd. Dr. Finan holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

 
Portrait

Peter Finan Ph.D., Epidarex Capital (Vice Chairman)

Dr. Peter Finan has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining Epidarex, Dr. Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Dr. Finan worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as the Head of Biology at Karus Therapeutics. Dr. Finan currently serves on the Board of Directors of Caldan Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd., Mironid Ltd., and Topas Therapeutics Ltd. Dr. Finan holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

 
Portrait

Dr. Werner Lanthaler, Evotec AG

Dr. Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Previously, from 1998 to 2000 Dr. Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. In April 2014, Dr. Lanthaler became a member of the Supervisory Board of arGEN-X.

 
Portrait

Dr. Werner Lanthaler, Evotec AG

Dr. Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Previously, from 1998 to 2000 Dr. Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. In April 2014, Dr. Lanthaler became a member of the Supervisory Board of arGEN-X.

 
Portrait

Karl Nägler, Gimv

Since 2011 Dr. Karl Nägler is working with Gimv’s Health and Care team as partner, he is located in Munich. Karl started his professional career in 2002 at Atlas Venture in London and Munich, he later joined Ventech, a Paris-based venture capital firm focused on Europe and China. Karl has a successful track record in early and later stage Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe. Previously, Karl had worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France) and holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine (Berlin) and a Diploma in Biology from the Free University of Berlin.

 
Portrait

Karl Nägler, Gimv

Since 2011 Dr. Karl Nägler is working with Gimv’s Health and Care team as partner, he is located in Munich. Karl started his professional career in 2002 at Atlas Venture in London and Munich, he later joined Ventech, a Paris-based venture capital firm focused on Europe and China. Karl has a successful track record in early and later stage Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe. Previously, Karl had worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France) and holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine (Berlin) and a Diploma in Biology from the Free University of Berlin.

 
Portrait

Dr. Jan Adams, EMBL Ventures

Dr. Jan Adams is a Managing Director with EMBL Ventures, focusing on opportunities in the drug development sector. He has been representing the firm on various portfolio boards, e.g., Lipid Therapeutics, Opsona, Arsanis and ViraTherapeutics. Prior to joining EMBL Ventures, Jan was a postdoctoral Fellow of the Ernst Schering Research Foundation at the University of Granada, Spain. Before that he was a Fellow of the Boehringer Ingelheim Research Foundation, conducting work on molecular transport mechanisms at the Wellcome CRC in Cambridge, UK. Jan holds a M.S. in Biochemistry & Molecular Biology from Tübingen University, Germany and completed a PhD in Genetics at the University of Cambridge, UK.

 
Portrait

Dr. Jan Adams, EMBL Ventures

Dr. Jan Adams is a Managing Director with EMBL Ventures, focusing on opportunities in the drug development sector. He has been representing the firm on various portfolio boards, e.g., Lipid Therapeutics, Opsona, Arsanis and ViraTherapeutics. Prior to joining EMBL Ventures, Jan was a postdoctoral Fellow of the Ernst Schering Research Foundation at the University of Granada, Spain. Before that he was a Fellow of the Boehringer Ingelheim Research Foundation, conducting work on molecular transport mechanisms at the Wellcome CRC in Cambridge, UK. Jan holds a M.S. in Biochemistry & Molecular Biology from Tübingen University, Germany and completed a PhD in Genetics at the University of Cambridge, UK.

 
Portrait

Dr. Detlev Mennerich, Boehringer Ingelheim Venture Fund

Detlev studied chemistry in Braunschweig (Germany) and Bordeaux (France) and holds a PhD in cell and molecular biology. In 2001, he started his industrial career at metaGen Pharmaceuticals GmbH and Schering AG in Berlin (Germany) as a Scientist in Oncogenomics focusing on target validation and biomarker research. In 2005, he joined Boehringer Ingelheim Pharma GmbH & Co.KG in Biberach an der Riss (Germany), where he held several positions: he started as laboratory head in Genomic Research for new drug concept nominations. In 2009, he moved to Ridgefield, CT (USA) as project leader for an anti-inflammatory antibody project. In 2011, Detlev returned to the Biberach site heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation. Beginning of 2014, he joined the BI Venture Fund investing in clinical translation of pioneering therapeutic approaches. Actually, he serves as board member of ViraTherapeutics GmbH in Innsbruck (Austria), Imcheck Therapeutics SAS in Marseille (France), HepaRegenix GmbH in Tübingen (Germany) and Topas Therapeutics GmbH in Hamburg (Germany).

 
Portrait

Dr. Detlev Mennerich, Boehringer Ingelheim Venture Fund

Detlev studied chemistry in Braunschweig (Germany) and Bordeaux (France) and holds a PhD in cell and molecular biology. In 2001, he started his industrial career at metaGen Pharmaceuticals GmbH and Schering AG in Berlin (Germany) as a Scientist in Oncogenomics focusing on target validation and biomarker research. In 2005, he joined Boehringer Ingelheim Pharma GmbH & Co.KG in Biberach an der Riss (Germany), where he held several positions: he started as laboratory head in Genomic Research for new drug concept nominations. In 2009, he moved to Ridgefield, CT (USA) as project leader for an anti-inflammatory antibody project. In 2011, Detlev returned to the Biberach site heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation. Beginning of 2014, he joined the BI Venture Fund investing in clinical translation of pioneering therapeutic approaches. Actually, he serves as board member of ViraTherapeutics GmbH in Innsbruck (Austria), Imcheck Therapeutics SAS in Marseille (France), HepaRegenix GmbH in Tübingen (Germany) and Topas Therapeutics GmbH in Hamburg (Germany).

 
Portrait

Dr. Erich F. Greiner, Cedrus Therapeutics

Dr. Erich Greiner founded Cedrus Therapeutics Inc. in May 2008 to develop novel therapeutic concepts and medicines. Before, Dr. Greiner held various senior positions within Evotec (FSE:EVT), at last as Chief Innovation Officer and Member of the Management Team of Evotec. Prior to joining Evotec, Dr. Greiner was a Research Associate at the German Research Cancer Center in Heidelberg. Dr. Greiner was trained in medicine and molecular biology at the University of Erlangen-Nürnberg and the Duke University Medical Center in Durham, NC, USA. Dr. Greiner serves as a strategic advisor and reviewer for several governmental, public and private institutions in the US and in Europe including the German Federal Ministry of Education and Research and the Federal Ministry for Health.

 
Portrait

Dr. Erich F. Greiner, Cedrus Therapeutics

Dr. Erich Greiner founded Cedrus Therapeutics Inc. in May 2008 to develop novel therapeutic concepts and medicines. Before, Dr. Greiner held various senior positions within Evotec (FSE:EVT), at last as Chief Innovation Officer and Member of the Management Team of Evotec. Prior to joining Evotec, Dr. Greiner was a Research Associate at the German Research Cancer Center in Heidelberg. Dr. Greiner was trained in medicine and molecular biology at the University of Erlangen-Nürnberg and the Duke University Medical Center in Durham, NC, USA. Dr. Greiner serves as a strategic advisor and reviewer for several governmental, public and private institutions in the US and in Europe including the German Federal Ministry of Education and Research and the Federal Ministry for Health.